LifeSplice was awarded a $3 million NIH Phase 2 SBIR grant for IND-enabling GLP Saftey + CMC studies of our lead drug LSP-GR1 for treating ALS. The grant will accelerate bringing LSP-GR1 to clinical trials in ALS patients by early 2017. LSP-GR1 is a highly specific and potent modulator of AMPA channel subunit alternative splicing, and functions to block excitotoxicity and preserve motor neurons.